Parametric Response Mapping of Apparent Diffusion Coefficient as an Imaging Biomarker to Distinguish Pseudoprogression from True Tumor Progression in Peptide-Based Vaccine Therapy for Pediatric Diffuse Intrinsic Pontine Glioma
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Parametric Response Mapping of Apparent Diffusion Coefficient as an Imaging Biomarker to Distinguish Pseudoprogression from True Tumor Progression in Peptide-Based Vaccine Therapy for Pediatric Diffuse Intrinsic Pontine Glioma
Authors
Keywords
-
Journal
AMERICAN JOURNAL OF NEURORADIOLOGY
Volume 36, Issue 11, Pages 2170-2176
Publisher
American Society of Neuroradiology (ASNR)
Online
2015-09-04
DOI
10.3174/ajnr.a4428
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Antigen-Specific Immune Responses and Clinical Outcome After Vaccination With Glioma-Associated Antigen Peptides and Polyinosinic-Polycytidylic Acid Stabilized by Lysine and Carboxymethylcellulose in Children With Newly Diagnosed Malignant Brainstem and Nonbrainstem Gliomas
- (2014) Ian F. Pollack et al. JOURNAL OF CLINICAL ONCOLOGY
- Precise ex vivo histological validation of heightened cellularity and diffusion-restricted necrosis in regions of dark apparent diffusion coefficient in 7 cases of high-grade glioma
- (2014) Peter S. LaViolette et al. NEURO-ONCOLOGY
- Challenges for the functional diffusion map in pediatric brain tumors
- (2013) M. Grech-Sollars et al. NEURO-ONCOLOGY
- Serial MR diffusion to predict treatment response in high-grade pediatric brain tumors: a comparison of regional and voxel-based diffusion change metrics
- (2013) D. Rodriguez Gutierrez et al. NEURO-ONCOLOGY
- Immunochemotherapy with Intensive Consolidation for Primary CNS Lymphoma: A Pilot Study and Prognostic Assessment by Diffusion-Weighted MRI
- (2012) M. J. Wieduwilt et al. CLINICAL CANCER RESEARCH
- Functional diffusion maps (fDMs) evaluated before and after radiochemotherapy predict progression-free and overall survival in newly diagnosed glioblastoma
- (2012) B. M. Ellingson et al. NEURO-ONCOLOGY
- Pseudoprogression and Pseudoresponse: Imaging Challenges in the Assessment of Posttreatment Glioma
- (2011) L.C. Hygino da Cruz et al. AMERICAN JOURNAL OF NEURORADIOLOGY
- Do we need novel radiologic response criteria for brain tumor immunotherapy?
- (2011) Hideho Okada et al. Expert Review of Neurotherapeutics
- FSL
- (2011) Mark Jenkinson et al. NEUROIMAGE
- Nipype: A Flexible, Lightweight and Extensible Neuroimaging Data Processing Framework in Python
- (2011) Krzysztof Gorgolewski et al. Frontiers in Neuroinformatics
- Validation of functional diffusion maps (fDMs) as a biomarker for human glioma cellularity
- (2010) Benjamin M. Ellingson et al. JOURNAL OF MAGNETIC RESONANCE IMAGING
- Volumetric analysis of functional diffusion maps is a predictive imaging biomarker for cytotoxic and anti-angiogenic treatments in malignant gliomas
- (2010) Benjamin M. Ellingson et al. JOURNAL OF NEURO-ONCOLOGY
- MR perfusion and diffusion imaging in the follow-up of recurrent glioblastoma treated with dendritic cell immunotherapy: a pilot study
- (2010) Matej Vrabec et al. NEURORADIOLOGY
- Distinguishing Glioma Recurrence from Treatment Effect After Radiochemotherapy and Immunotherapy
- (2009) Isaac Yang et al. NEUROSURGERY CLINICS OF NORTH AMERICA
- Imaging Immune Response In vivo: Cytolytic Action of Genetically Altered T Cells Directed to Glioblastoma Multiforme
- (2008) J. Lazovic et al. CLINICAL CANCER RESEARCH
- Fractional anisotropy and tumor cell density of the tumor core show positive correlation in diffusion tensor magnetic resonance imaging of malignant brain tumors
- (2008) Manabu Kinoshita et al. NEUROIMAGE
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started